News & Updates
Filter by Specialty:
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
In patients with non-muscle-invasive bladder cancer (NMIBC), high-grade (HG) recurrence after bacillus Calmette-Guérin (BCG) treatment is associated with T-cell exhaustion, according to a study.
T-cell exhaustion tied to post-BCG recurrence in bladder cancer
07 Nov 2022
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
04 Nov 2022
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
02 Nov 2022
Real-world data affirms palbociclib–AI combo efficacy in metastatic breast cancer
The use of the combination of palbociclib plus an aromatase inhibitor (AI) in the first-line treatment setting appears to confer survival advantage on patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC), according to real-world data.